Buy Letrozole Femara from us the best online pharmacy online now. Letrozole tablets for oral administration contain 2.5 mg of letrozole, a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis).
Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31, empirical formula C17H11N5, and a melting range of 184°C to 185°C.
To add to the about, Femara is available as 2.5 mg tablets for oral administration.
Colloidal silicon dioxide, ferric oxide, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide.
DOSAGE AND ADMINISTRATION
The recommended dose of Femara is one 2.5 mg tablet administered once a day, without regard to meals.
Use In Adjuvant Treatment Of Early Breast Cancer
In the adjuvant setting, the optimal duration of treatment with letrozole is unknown. In both the adjuvant study and the post-approval adjuvant study, the median treatment duration was 5 years. Treatment should be discontinued at relapse [see Clinical Studies].
Use In Extended Adjuvant Treatment Of Early Breast Cancer
In the extended adjuvant setting, the optimal treatment duration with Femara is not known.
The planned duration of treatment in the study was 5 years. In the final updated analysis, conducted at a median follow-up of 62 months, the median treatment duration for Femara was 60 months.
Seventy-one (71%) percent of patients were treated for at least 3 years and 58% of patients completed at least 4.5 years of extended adjuvant treatment. The treatment should be discontinued at tumor relapse [see Clinical Studies].
Use In First And Second-Line Treatment Of Advanced Breast Cancer
In patients with advanced disease, treatment with Femara should continue until tumor progression is evident [see Clinical Studies].
Use In Hepatic Impairment
No dosage adjustment is recommended for patients with mild to moderate hepatic impairment, although Femara blood concentrations were modestly increased in subjects with moderate hepatic impairment due to cirrhosis.
The dose of Femara in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see WARNINGS AND PRECAUTIONS].
The recommended dose of Femara for such patients is 2.5 mg administered every other day.
The effect of hepatic impairment on Femara exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined. Buy Letrozole Femara only from Online media supply because we have the best quality
Use In Renal Impairment
furthermore, no dosage adjustment is required for patients with renal impairment if creatinine clearance is greater than or equal to 10 mL/min [see CLINICAL PHARMACOLOGY].
Dosage Forms And Strengths
In addition, l2.5 mg tablets: dark yellow, film-coated, round, slightly biconvex, with beveled edges (imprinted with the letters FV on one side and CG on the other side). Buy Letrozole Femara from now so that we can give you the best dosage
Storage And Handling
Packaged in HDPE bottles with a safety screw cap.
2.5 mg tablets
Bottles of 30 tablets – NDC 0078-0249-15
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].